Compare ZURA & RLTY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ZURA | RLTY |
|---|---|---|
| Founded | 2022 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 252.9M | 247.3M |
| IPO Year | N/A | N/A |
| Metric | ZURA | RLTY |
|---|---|---|
| Price | $4.31 | $14.42 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $11.38 | N/A |
| AVG Volume (30 Days) | ★ 369.0K | 86.7K |
| Earning Date | 11-13-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 9.35% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.97 | $11.38 |
| 52 Week High | $4.68 | $14.60 |
| Indicator | ZURA | RLTY |
|---|---|---|
| Relative Strength Index (RSI) | 65.25 | 30.76 |
| Support Level | $3.88 | $14.52 |
| Resistance Level | $4.45 | $14.69 |
| Average True Range (ATR) | 0.25 | 0.17 |
| MACD | 0.05 | -0.04 |
| Stochastic Oscillator | 89.36 | 14.46 |
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.
Cohen & Steers Real Estate Opportunities and Income Fund is an organized, non-diversified, closed-end management investment company. The Fund's primary investment objective is high current income. The Fund's secondary investment objective is capital appreciation.